Agios Pharmaceuticals’ (AGIO) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Friday morning, Benzinga reports.

Several other equities research analysts also recently weighed in on the stock. JPMorgan Chase & Co. restated a neutral rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, June 13th. The Goldman Sachs Group raised their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the company a neutral rating in a research note on Tuesday, June 4th. StockNews.com downgraded shares of Agios Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, August 5th. Finally, Royal Bank of Canada restated an outperform rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Hold and an average price target of $51.33.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $45.76 on Friday. The firm’s 50 day moving average price is $45.68 and its 200-day moving average price is $39.34. Agios Pharmaceuticals has a 52-week low of $19.80 and a 52-week high of $50.35. The company has a market cap of $2.60 billion, a PE ratio of -7.24 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.60) by ($0.09). The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. Agios Pharmaceuticals’s revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the business earned ($1.51) earnings per share. On average, analysts forecast that Agios Pharmaceuticals will post -4.85 earnings per share for the current fiscal year.

Insider Transactions at Agios Pharmaceuticals

In related news, CEO Brian Goff sold 11,091 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the completion of the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter worth $37,000. Quest Partners LLC purchased a new position in shares of Agios Pharmaceuticals during the second quarter worth $40,000. NEOS Investment Management LLC purchased a new position in shares of Agios Pharmaceuticals during the fourth quarter worth $210,000. North Star Asset Management Inc. purchased a new position in shares of Agios Pharmaceuticals during the second quarter worth $216,000. Finally, XTX Topco Ltd purchased a new position in Agios Pharmaceuticals in the second quarter valued at $230,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.